about
The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, RussiaA new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Challenges in the clinical assessment of novel tuberculosis drugs.Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in ZambiaEvaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.When inferiority meets non-inferiority: implications for interim analyses.Donepezil and memantine for moderate-to-severe Alzheimer's disease.An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.Four-month moxifloxacin-based regimens for drug-sensitive tuberculosisA multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosisLimited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals.Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trialRandomized clinical trials to identify optimal antibiotic treatment durationDesign issues in pivotal drug trials for drug sensitive tuberculosis (TB).DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTPrinciples for designing future regimens for multidrug-resistant tuberculosis.Adaptive clinical trials in tuberculosis: applications, challenges and solutions.Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.Determining the minimum clinically important differences for outcomes in the DOMINO trial.Short intensified treatment in children with drug-susceptible tuberculous meningitis.Timing of relapse in short-course chemotherapy trials for tuberculosis.Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months?Reply to Dodd and Proschan.A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.Biomarkers for tuberculosis disease activity, cure, and relapse.The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs.An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd.Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.
P50
Q28551241-7930C098-7DA3-48A6-9712-3ED54015217AQ28602112-D5E2D687-68C1-4AF2-A343-50DD33F92103Q30251933-F0FB6EA8-B253-4DBF-A76C-5185DEF89F67Q34108680-16203C9D-A92F-4C19-9270-EC2F6849FAEDQ34184543-1B733B28-910F-4578-B59F-1F534A7FE978Q34337738-338CC81D-BCC5-4572-863F-9B1216525FB4Q34636487-3EFDF6DA-7FDE-4E37-93F8-E0D8C9308D67Q34718431-5F77F950-5E18-4DCC-BD36-7B68F633E52CQ34777926-2F10887A-AFA4-4047-8829-CE6D29C71360Q35042658-616A0D3F-4A33-49FF-A7AD-BE096EC6988CQ35915044-B5F2BC58-3F08-447B-8F02-CB053677623DQ36194935-E4980F74-2041-43A6-96E0-9147CAF83DF6Q36325978-840DE041-4848-4702-B033-1A3881C9DCD5Q36755487-A458870A-007D-4812-802C-C8A05F5CB9CFQ37257905-46174D42-BB12-4FC6-B32C-4037E8E95815Q37295359-D5DDF16E-2D6E-471B-B3CB-2D3BB69CF5B8Q37398037-3CA76F1D-5C05-40B3-8C78-49D0D2FF14B5Q38462203-D0F9C685-3CB1-4ED4-ACE7-57FF04B89957Q38623426-B335388D-FAE9-4913-8BF5-A17185636436Q38918532-5E209274-04AE-461D-9421-8AA9F8F3AECEQ39012547-D7CC28F0-EA20-4B70-9E26-E6379D39BAB6Q39014202-5329946A-3570-484B-B3B9-BA96139457DAQ39769344-74DBC84E-46BE-46C4-A561-76C03512BB02Q41169867-35C9FC6E-E875-48DC-9B4F-43997EBE9F4DQ41444380-EBF8D706-F4A9-47F5-8D5E-C8FB11BDF054Q41857207-58137E66-E1C6-4B21-87FD-B06C5475789CQ42588101-01B7B96A-31BB-4FD0-8E42-3689749BF2D2Q42675662-953E6AE9-29AE-41D2-95CC-FD9B3EE21C2DQ42813201-C9B6D38B-C984-4606-9392-95A395EB8936Q43488989-339FB836-9302-4208-91E8-48AB5382627BQ43608012-022DE368-1743-4F44-8901-6B18984C07DEQ43823439-9F19863B-E536-475A-82F7-54676D1B82AAQ44653758-A059C5EB-BD12-4EBD-8221-2B90A1D5EB04Q46046130-5E078B69-F50D-473B-8E30-A1180C20243FQ46285505-7AB4AF96-320A-4151-9A85-A98C4BD2BD0DQ46743569-AA51668A-4D96-46AD-BFF6-A2AEAA802BC7Q47100507-DAD455DF-4322-436E-92F4-D7036D5B3FC0Q47163824-F72D8F5F-3115-46E7-A01C-814165943B85Q48162194-C36A30CA-83DC-4A7A-BAF0-AEFED6335B1FQ50498479-5373EF14-D0DE-41A1-9E49-8B8C2679ECE4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Patrick Phillips
@ast
Patrick Phillips
@en
Patrick Phillips
@es
Patrick Phillips
@nl
Patrick Phillips
@sl
type
label
Patrick Phillips
@ast
Patrick Phillips
@en
Patrick Phillips
@es
Patrick Phillips
@nl
Patrick Phillips
@sl
prefLabel
Patrick Phillips
@ast
Patrick Phillips
@en
Patrick Phillips
@es
Patrick Phillips
@nl
Patrick Phillips
@sl
P1053
B-6347-2008
P106
P21
P31
P3829
P496
0000-0002-6336-7024